Elwan Nadia, Amr Khalda, Elyamany Sahar, Elkhalawany Walaa, Soliman Shaimaa, Ziada Mohamed, Abd-Elsalam Sherief
Tropical Medicine & Infectious Diseases Department, Tanta University Faculty of Medicine, Tanta, Egypt.
Molecular Medical Genetics Department, National Research Center (NRC), Cairo, Egypt.
Infect Disord Drug Targets. 2018;18(2):122-128. doi: 10.2174/1871526517666170606103533.
BACKGROUND & AIMS: Cell-mediated immunity plays a critical role in viral clearance and disease progression during Hepatitis C virus (HCV) infection. Interleukin (IL)-12 is a cytokine that has been shown to be a potent antiviral cytokine. The aim of this work is to investigate the association of IL-12 B gene polymorphism with staging of liver disease in chronic HCV patients.
This cross sectional study was carried out in tropical medicine department, Tanta university hospital, Egypt, on 120 chronic HCV patients with various stages of liver disease and 30 healthy subjects served as control. All the participants were tested for IL- 12 B (p40) gene polymorphism.
the frequency of AA genotype was higher in HCV patients with decompensated cirrhosis and in HCV patients with Hepatocellular carcinoma (HCC). However, the CC genotype was less detected in all groups, with the lowest percentage (6.6%) detected in decompensated cirrhosis and HCC patients.
AA genotype presented more frequently in late stages of HCV chronically ill patients, while, CC genotype had no significant association with staging of liver disease and had low frequency especially in late stages of liver disease.
细胞介导的免疫在丙型肝炎病毒（HCV）感染期间的病毒清除和疾病进展中起关键作用。白细胞介素（IL）-12是一种已被证明具有强大抗病毒作用的细胞因子。本研究旨在探讨慢性HCV患者中IL-12 B基因多态性与肝病分期的相关性。
本横断面研究在埃及坦塔大学医院热带医学科进行，纳入120例处于不同肝病阶段的慢性HCV患者，并选取30名健康受试者作为对照。所有参与者均接受IL-12 B（p40）基因多态性检测。
失代偿期肝硬化的HCV患者和肝细胞癌（HCC）的HCV患者中AA基因型频率较高。然而，所有组中CC基因型检出较少，在失代偿期肝硬化和HCC患者中检出率最低（6.6%）。
AA基因型在慢性HCV患者的晚期更为常见，而CC基因型与肝病分期无显著相关性，且频率较低，尤其是在肝病晚期。
